Current Understanding of Urachal Adenocarcinoma and Management Strategy

被引:40
作者
Claps, Melanie [1 ]
Stellato, Marco [1 ]
Zattarin, Emma [1 ]
Mennitto, Alessia [1 ]
Sepe, Pierangela [1 ]
Guadalupi, Valentina [1 ]
Mennitto, Roberta [1 ]
de Braud, Filippo G. M. [1 ]
Verzoni, Elena [1 ]
Procopio, Giuseppe [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol, Milan, Italy
关键词
Urachal carcinoma; Update in diagnosis; Molecular biology; Target therapy; Chemotherapy; Immunotherapy; MICROSATELLITE-INSTABILITY; PALLIATIVE CHEMOTHERAPY; EPITHELIAL NEOPLASMS; PARTIAL CYSTECTOMY; CARCINOMA; CANCER; BLADDER; FLUOROURACIL; PANITUMUMAB; DOXORUBICIN;
D O I
10.1007/s11912-020-0878-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. Recent Findings UC is a rare and aggressive disease with consequent few data about diagnosis and treatment. Dates are mainly based on retrospective trial and case reports with limited prospective trial. Clinical presentation is not specific, often with urinary symptoms. Diagnosis is mainly based on CT scan and MRI, useful to evaluate local invasion and nodal status and to detect the presence of distant metastases. Therefore, biopsy is needed to obtain histological confirmation. Surgery is the gold standard for localized disease, while different chemotherapy schemes have been used in metastatic setting. Novel findings based on mutational analysis of the tumor include the use of biological treatment, such as cetuximab, and immunotherapy, such as atezolizumab, with satisfactory responses, suggesting that personalized treatment could be the most suitable option for UC.
引用
收藏
页数:8
相关论文
共 64 条
[11]   National incidence, management and survival of urachal carcinoma [J].
Collins, Dearbhaile C. ;
Velazquez-Kennedy, Kyra ;
Deady, Sandra ;
Brady, Adrian P. ;
Sweeney, Paul ;
Power, Derek G. .
RARE TUMORS, 2016, 8 (03) :97-101
[12]   Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer [J].
Corcoran, Ryan B. ;
Atreya, Chloe E. ;
Falchook, Gerald S. ;
Kwak, Eunice L. ;
Ryan, David P. ;
Bendell, Johanna C. ;
Hamid, Omid ;
Messersmith, Wells A. ;
Daud, Adil ;
Kurzrock, Razelle ;
Pierobon, Mariaelena ;
Sun, Peng ;
Cunningham, Elizabeth ;
Little, Shonda ;
Orford, Keith ;
Motwani, Monica ;
Bai, Yuchen ;
Patel, Kiran ;
Venook, Alan P. ;
Kopetz, Scott .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :4023-+
[13]  
Dadhania V, 2015, AM J CLIN EXP UROL, V3, P51
[14]   Urachal carcinoma: a pathologic and clinical study of 46 cases [J].
Dhillon, Jasreman ;
Liang, Yu ;
Kamat, Ashish M. ;
Siefker-Radtke, Arlene ;
Dinney, Colin P. ;
Czerniak, Bogdan ;
Guo, Charles C. .
HUMAN PATHOLOGY, 2015, 46 (12) :1808-1814
[15]   Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].
Di Nicolantonio, Federica ;
Martini, Miriam ;
Molinari, Francesca ;
Sartore-Bianchi, Andrea ;
Arena, Sabrina ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Mazzucchelli, Luca ;
Frattini, Milo ;
Siena, Salvatore ;
Bardelli, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712
[16]   Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient [J].
Doll, Sophia ;
Kriegmair, Maximilian C. ;
Santos, Alberto ;
Wierer, Michael ;
Coscia, Fabian ;
Neil, Helen Michele ;
Porubsky, Stefan ;
Geyer, Philipp E. ;
Mund, Andreas ;
Nuhn, Philipp ;
Mann, Matthias .
MOLECULAR ONCOLOGY, 2018, 12 (08) :1296-1307
[17]   A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens [J].
Elser, Christine ;
Sweet, Joan ;
Cheran, Sendhil K. ;
Haider, Masoom A. ;
Jewett, Michael ;
Sridhar, Srikala S. .
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2012, 6 (01) :E27-E31
[18]   Urachal Carcinoma A Clinicopathologic Analysis of 24 Cases With Outcome Correlation [J].
Gopalan, Anuradha ;
Sharp, David S. ;
Fine, Samson W. ;
Tickoo, Satish K. ;
Herr, Harry W. ;
Reuter, Victor E. ;
Olgac, Semra .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (05) :659-668
[19]   A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group [J].
Goss, G ;
Hirte, H ;
Miller, WH ;
Lorimer, IAJ ;
Stewart, D ;
Batist, G ;
Parolin, DAE ;
Hanna, P ;
Stafford, S ;
Friedmann, J ;
Walsh, W ;
Mathews, S ;
Douglas, L ;
Seymour, LK .
INVESTIGATIONAL NEW DRUGS, 2005, 23 (02) :147-155
[20]   Urachal carcinoma: Contemporary surgical outcomes [J].
Herr, Harry W. ;
Bochner, Bernard H. ;
Sharp, David ;
Dalbagni, Guido ;
Reuter, Victor E. .
JOURNAL OF UROLOGY, 2007, 178 (01) :74-78